[Gastric lesion caused by NSAID and inflammation due to Helicobacter pylori. Is there potentiation or attenuation?].
Lanas Arbeloa
A
A
Servicio de Aparato Digestivo, Hospital Clínico Universitario, Zaragoza.
Serrano Aulló
M T
MT
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D016001:Confidence Intervals; D004381:Duodenal Ulcer / Q000139:chemically induced / Q000188:drug therapy / Q000209:etiology; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005756:Gastritis / Q000139:chemically induced* / Q000209:etiology*; D016481:Helicobacter Infections / Q000150:complications* / Q000188:drug therapy; D016480:Helicobacter pylori; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D015337:Multicenter Studies as Topic; D009288:Naproxen / Q000627:therapeutic use; D009853:Omeprazole / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000139:chemically induced* / Q000188:drug therapy / Q000209:etiology*; D011446:Prospective Studies; D011899:Ranitidine / Q000627:therapeutic use; D012307:Risk Factors; D013276:Stomach Ulcer / Q000139:chemically induced / Q000188:drug therapy / Q000209:etiology
D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents; D004791:Enzyme Inhibitors; D006635:Histamine H2 Antagonists; D009288:Naproxen; D011899:Ranitidine; D009853:Omeprazole